NewGenIVF to Invest in K25.ai Prediction Market at $100M Valuation
NewGenIVF invests $2M in K25.ai prediction market at $100M valuation, with option for $10M more and board expansion across...
Tevogen Bio Pursues Management Services Organization Acquisition
Tevogen Bio evaluates management services organization acquisition as part of infrastructure expansion strategy alongside CRO operations.
GENFIT Q1 2026 Royalties Jump 243% on Ipsen Iqirvo Sales
GENFIT's Q1 2026 royalties surged 243% driven by Ipsen Iqirvo sales reaching €78.8M, securing €136.1M cash and extended runway.
Scilex to Distribute 10.7M Semnur Shares to Shareholders June 1
Scilex to distribute 10.7M Semnur shares to shareholders on June 1, creating a standalone public vehicle for the Phase...
Liminatus Pharma to Acquire InnocsAI’s CAR-T Pipeline for $320M in Stock
Liminatus Pharma acquires InnocsAI's CAR-T pipeline for $320M in stock, adding dual-antigen and solid tumor programs to its oncology...
PharmAla Licenses ALA-002 MDMA Rights to Jupiter Neurosciences in $100M Deal
PharmAla licenses ALA-002 MDMA rights to Jupiter Neurosciences in $100M deal with non-racemic compound gaining FDA Novel Chemical Entity...
Scilex to Distribute Semnur Shares to Stockholders via Dividend
Scilex to distribute roughly 10.7 million Semnur shares to stockholders while retaining majority control of the pharmaceutical company.
Liminatus Pharma to Acquire InnocsAI in $320M All-Stock Deal
Liminatus Pharma acquires InnocsAI for $320M in all-stock deal to advance bivalent CAR-T oncology programs with dual-antigen targeting.
GENFIT Royalty Revenue Triples on Ipsen Iqirvo Sales Growth
Ipsen Iqirvo sales reached €78.8M in Q1, driving GENFIT's royalty revenue to €9.6M and triggering early milestone payments.
PharmAla Licenses MDMA Candidate ALA-002 to Jupiter Neurosciences for $100M
PharmAla licenses MDMA Candidate ALA-002 to Jupiter Neurosciences for $100M, gaining NCE regulatory designation and U.S. commercialization rights.